ALKS

ALKS

USD

Alkermes plc Ordinary Shares

$30.480+0.480 (1.600%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
愛爾蘭

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$30.000

最高

$30.630

最低

$29.770

交易量

0.42M

公司基本面

市值

5.0B

行業

Drug Manufacturers - Specialty & Generic

國家

Ireland

交易統計

平均交易量

2.00M

交易所

NMS

貨幣

USD

52週範圍

最低 $25.17當前 $30.480最高 $36.45

相關新聞

Analyst Upgrades

Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42

Wells Fargo analyst Benjamin Burnett maintains Alkermes with a Overweight and lowers the price target from $44 to $42.

查看更多
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42
Analyst Upgrades

Needham Maintains Buy on Alkermes, Raises Price Target to $44

Needham analyst Ami Fadia maintains Alkermes with a Buy and raises the price target from $43 to $44.

查看更多
Needham Maintains Buy on Alkermes, Raises Price Target to $44
PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...

查看更多
Alkermes plc Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45

Mizuho analyst Uy Ear maintains Alkermes with a Outperform and raises the price target from $40 to $45.

查看更多
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45
Analyst Upgrades

Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45

Piper Sandler analyst David Amsellem reiterates Alkermes with a Overweight and raises the price target from $38 to $45.

查看更多
Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45
Analyst Upgrades

RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $47

RBC Capital analyst Leonid Timashev maintains Alkermes with a Outperform and raises the price target from $45 to $47.